← All trials
NCT04911166
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Jun 2, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The University of Texas, DallasLead sponsor
- The University of Texas, DallasReponsible party - principal investigator
- GenentechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.